BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35332633)

  • 1. Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia.
    Sekiguchi N; Rai S; Munakata W; Suzuki K; Handa H; Shibayama H; Endo T; Terui Y; Iwaki N; Fukuhara N; Tatetsu H; Iida S; Ishikawa T; Iguchi D; Izutsu K
    Cancer Sci; 2022 Jun; 113(6):2085-2096. PubMed ID: 35332633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
    Sekiguchi N; Rai S; Munakata W; Suzuki K; Handa H; Shibayama H; Endo T; Terui Y; Iwaki N; Fukuhara N; Tatetsu H; Iida S; Ishikawa T; Shiibashi R; Izutsu K
    Cancer Sci; 2020 Sep; 111(9):3327-3337. PubMed ID: 32639651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Tirabrutinib Monotherapy for Bing-Neel Syndrome in Waldenström's Macroglobulinemia.
    Sekiguchi N
    Intern Med; 2022 Dec; 61(23):3473-3474. PubMed ID: 35569973
    [No Abstract]   [Full Text] [Related]  

  • 4. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
    Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
    Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
    Furman RR; Eradat HA; DiRienzo CG; Hofmeister CC; Hayman SR; Leonard JP; Coleman M; Advani R; Chanan-Khan A; Switzky J; Liao QM; Shah D; Jewell RC; Lisby S; Lin TS
    Lancet Haematol; 2017 Jan; 4(1):e24-e34. PubMed ID: 27914971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström's Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study.
    Yi S; Cai Z; Hu Y; He A; Gao S; Li Q; Sha L; Zhang N; Ren Y; Gai X; Yang X; Qin R; Qiu L
    Adv Ther; 2024 Feb; 41(2):672-685. PubMed ID: 38079089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R
    Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
    Dimopoulos MA; Tedeschi A; Trotman J; García-Sanz R; Macdonald D; Leblond V; Mahe B; Herbaux C; Tam C; Orsucci L; Palomba ML; Matous JV; Shustik C; Kastritis E; Treon SP; Li J; Salman Z; Graef T; Buske C;
    N Engl J Med; 2018 Jun; 378(25):2399-2410. PubMed ID: 29856685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.
    D'Aveni-Piney M; Divoux M; Busby-Venner H; Muller M; Broséus J; Feugier P
    J Med Case Rep; 2018 Jun; 12(1):164. PubMed ID: 29890999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
    Grunenberg A; Buske C
    Future Oncol; 2019 Aug; 15(23):2687-2697. PubMed ID: 31184501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
    Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
    J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up.
    Trotman J; Opat S; Gottlieb D; Simpson D; Marlton P; Cull G; Munoz J; Tedeschi A; Roberts AW; Seymour JF; Atwal SK; Yu Y; Novotny W; Holmgren E; Tan Z; Hilger JD; Huang J; Tam CS
    Blood; 2020 Oct; 136(18):2027-2037. PubMed ID: 32698195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Investig Drugs; 2017 Feb; 26(2):197-205. PubMed ID: 28043164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.
    Papanota AM; Ntanasis-Stathopoulos I; Kastritis E; Dimopoulos MA; Gavriatopoulou M
    J Blood Med; 2019; 10():291-300. PubMed ID: 31695539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma followed by Waldenström's macroglobulinemia: a case report.
    Hasegawa K; Kubota K; Hirai H; Imai Y; Midorikawa Y; Makuuchi M
    Hepatogastroenterology; 2000; 47(33):842-5. PubMed ID: 10919044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
    Ghobrial IM; Roccaro A; Hong F; Weller E; Rubin N; Leduc R; Rourke M; Chuma S; Sacco A; Jia X; Azab F; Azab AK; Rodig S; Warren D; Harris B; Varticovski L; Sportelli P; Leleu X; Anderson KC; Richardson PG
    Clin Cancer Res; 2010 Feb; 16(3):1033-41. PubMed ID: 20103671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Complete response with tirabrutinib for relapsed and refractory Bing-Neel syndrome].
    Hagihara M; Ide S; Ohara S; Imai Y; Uchida T; Inoue M
    Rinsho Ketsueki; 2022; 63(7):770-775. PubMed ID: 35922946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment with tirabrutinib for relapsed Bing-Neel syndrome following high-dose methotrexate and craniospinal irradiation.
    Saburi M; Sakata M; Okuhiro K; Kawano K; Uesugi S; Wada J; Urabe S; Saburi Y; Ohtsuka E
    J Clin Exp Hematop; 2022; 62(3):181-186. PubMed ID: 36171098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia.
    Hunter ZR; Manning RJ; Hanzis C; Ciccarelli BT; Ioakimidis L; Patterson CJ; Lewicki MC; Tseng H; Gong P; Liu X; Zhou Y; Yang G; Sun J; Xu L; Sheehy P; Morra M; Treon SP
    Haematologica; 2010 Mar; 95(3):470-5. PubMed ID: 19903677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.